Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Nasdaq16d
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after market close. The Zacks Consensus Estimate for sales and earnings is ...
rarediseaseadvisor24d
Seladelpar Leads to Clinically Meaningful Improvements in PBC
52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...
The Pharma Letter26d
FDA approves Ozempic for patients with diabetes and CKD
In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...
PMLiVE1mon
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...
Business Insider1mon
Seladelpar approved to treat adult patients in the U.K. with liver illness
The Medicines and Healthcare products Regulatory Agency has approved the medicine seladelpar in adults for the treatment of a liver illness called Primary Biliary Cholangitis, including pruritus.
rarediseaseadvisor1mon
Seladelpar Improves Biochemical Markers and Pruritus in PBC
Seladelpar leads to improvements in biochemical markers and pruritus in patients with primary biliary cholangitis (PBC), according to interim results from an open-label, long-term, phase 3 clinical ...